Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held on Wednesday, November 12, 2025, inter-alia considered and approved the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2025. A copy of the same is enclosed along with the Limited Review Report of the Statutory Auditors thereon in terms of SEBI (LODR) Regulations, 2015.The Meeting of the Board of Directors of the Company commenced at 03:00 p.m. and concluded at 03.30 p.m.Kindly take the above information on your records.
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Supriya Lifescience approved the unaudited financial results for the quarter and half year ended September 30, 2025 at a meeting held on November 12, 2025. The meeting lasted 30 minutes, from 3:00 p.m. to 3:30 p.m. The filing also includes the Limited Review Report from the statutory auditors, as required under SEBI listing rules. No specific financial figures are disclosed in this filing; the detailed results are enclosed as an attachment.
This is a routine procedural disclosure confirming board approval of quarterly results. Investors should look at the attached financial results for actual performance numbers, which are not shared in this filing text.